Cryolife Hydrogel Technology Provides Platform For Diverse Pipeline
This article was originally published in The Gray Sheet
Atlanta-based Cryolife is preparing for human trials to support approval of its BioDisc spinal disc repair system and plans to file for an FDA investigational device exemption in the first half of 2005
You may also be interested in...
Raymedica and Interpore Cross are readying internally-developed artificial spinal disc offerings for U.S. market entry behind J&J/DePuy Acromed, Medtronic/Sofamor Danek and Synthes-Stratec - three companies competing through recent acquisitions
CryoLife credits San Francisco-based Acumen Sciences for guiding it through an FDA Form 483 and a subsequent recall of cardiac, orthopedic and vascular tissue products
The Securities and Exchange Commission is seeking information from CryoLife on corporate accounting from October 2001 to the present related to a company recall of tissue products, as well as stock trading activity